Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Auspex Pharmaceuticals Inc (ASPX): Deerfield Management Increase its Stake Following the Latest Public Offering of Stock

James E. Flynn’s Deerfield Management recently increased its stake in Auspex Pharmaceuticals Inc (NASDAQ:ASPX) by 1.5 million shares at $56.5 per share. According to the Form 4 filed with the U.S. Securities and Exchange Commission, the investment firm purchased these shares on the open market in several transactions and now owns a total of 4.4 million Common Shares.

Deerfield Management is a New York City-based hedge fund that was launched in 1994 and has been managed by James E. Flynn since 2000. The firm invests primarily in equities from the health care sector, displaying extensive knowledge and a comprehensive understanding of the factors at play in this industry. Furthermore, the fund has specialized in corporate transitions, managing hostile takeovers, funding research and development, as well as in providing financial advisory services. Deerfield Management currently has $4.4 billion in assets under management and boasts an equity portfolio valued at $2.7 billion.

Auspex Pharmaceuticals, Inc. (ASPX)

According to its last 13F filing, the hedge fund’s largest holding was in Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) stock and represented 6.8% of its equity portfolio. The investment firm’s other top picks included Allergan, Inc. (NYSE:AGN) and NxStage Medical, Inc. (NASDAQ:NXTM), although each of these position only accounted for around 3% of Deerfield Management’s total holdings. Furthermore, the hedge fund disclosed a significant increase to its stake in Vanda Pharmaceuticals Inc (NASDAQ:VNDA) at the end of 2014. Following this recent transaction, the firm became one of the company’s largest institutional investors.

Deerfield Management disclosed the acquisition of its initial stake in Auspex Pharmaceuticals Inc (NASDAQ:ASPX) at the end of the first quarter of 2014. From the end of the third quarter to the hedge fund’s latest purchase of shares, the stock had gained a whopping 95%, growing by 278% since the company first went public in February of last year. Furthermore, the pharmaceutical company recently announced the underwritten public offering of an additional 4 million shares of common stock. This allowed Deerfield Management to increase its exposure to Auspex considerably, thus becoming its largest institutional investor.

Auspex Pharmaceuticals Inc (NASDAQ:ASPX) was the second-best IPO of 2014, gaining 218% throughout the past year, after the stock opened for trade at $12 per share. Deerfield Management initially disclosed owning 1.29 million Class E Preferred Shares of Auspex after the stock went public, acquiring an additional stake of 700,000 shares of Common Stock a week later. Whether share prices will continue to climb over the next quarter as they did in 2014 is uncertain, yet the hedge fund managed by Mr. Flynn seems to feel optimistic regarding the stock’s future performance.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.